By ANDREW POLLACK
Alarmed by soaring prices for cancer drugs, the leading American oncology society has devised a “value framework” to evaluate treatments by effectiveness, side effects and cost.
Published: June 23, 2015 at 12:00AM
from NYT Business Day http://ift.tt/1Iae1lW
from WordPress http://ift.tt/1J0vEmQ
via Hadi Aboukhater
No comments:
Post a Comment